Compare Ascendis Pharma A/S (ASND) vs Ginkgo Bioworks Holdings Inc (DNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Ginkgo Bioworks Holdings Inc — how do they compare? Ascendis Pharma A/S trades at $255.5 (market cap $16.67B), while Ginkgo Bioworks Holdings Inc trades at $7.57 (market cap $505.73M). The key difference: Ascendis Pharma A/S is far larger — about 33× Ginkgo Bioworks Holdings Inc's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Ginkgo Bioworks Holdings Inc nearer its low. Which is the better fit depends on your goals.
| ASND | DNA | |
|---|---|---|
Market Cap | $16.67B | $505.73M |
Sector | Health | Health |
52-Week High | $277.18 | $16.14 |
52-Week Low | $189.74 | $5.48 |
Enterprise Value | $17.04B | $607.68M |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →
